INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseGlobeNewsWire • 05/14/26
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection PointGlobeNewsWire • 05/13/26
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business UpdateGlobeNewsWire • 05/07/26
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory DiseasesGlobeNewsWire • 05/05/26
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7thGlobeNewsWire • 04/30/26
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.GlobeNewsWire • 03/24/26
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease TranscriptSeeking Alpha • 02/27/26
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB TranscriptSeeking Alpha • 02/27/26
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's WebinarGlobeNewsWire • 02/23/26
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEBGlobeNewsWire • 02/19/26
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic InitiativesGlobeNewsWire • 01/27/26
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ PlatformGlobeNewsWire • 12/05/25
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's PatientsGlobeNewsWire • 12/01/25
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD ConferenceGlobeNewsWire • 11/18/25
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 11/06/25
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business UpdateGlobeNewsWire • 10/30/25
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025GlobeNewsWire • 10/14/25
INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 09/08/25